iBio, Inc.(IBIO)

Description: iBio, Inc., a biotechnology company, engages in the development and commercialization of vaccines and therapeutic proteins through its proprietary iBioLaunch platform technology in the United States. Its product portfolio includes seasonal and H1N1 influenza vaccines for the seasonal influenza virus strains; pandemic avian influenza vaccine for the pathogenic avian influenza viruses; and therapeutic vaccines for human papilloma virus. The company also offers biodefense products, including oral anthrax booster vaccine candidates and candidate plague vaccines. In addition, it provides therapeutic protein product candidates comprising human alpha-galactosidase A for the treatment of Fabry disease; human C-1 esterase inhibitor for the treatment of hereditary angioedema; and human alpha-1 antitrypsin for treatment of disorders caused by a deficiency of alpha-1 antitrypsin. Further, the company offers vaccine enhancements through its iBioModulator platform. It has a license and collaboration agreement with Caliber Biotherapeutics, LLC for the development and production of recombinant plant-based biopharmaceuticals. The company is headquartered in Newark, Delaware.

---

Keywords: Medicine Biotechnology Biopharmaceutical Vaccines Disorders Influenza Vaccination Microbiology Viruses Platform Technology Deficiency Defense Products Hereditary Angioedema Angioedema Influenza Vaccine Biodefense Fabry Disease Human Papilloma Virus Seasonal Influenza Anthrax Avian Influenza Influenza Viruses H1 N1 Influenza Live Attenuated Influenza Vaccine Treatment Of Fabry Disease

---

Home Page: www.ibioinc.com

IBIO Technical Analysis

8800 HSC Parkway
Bryan, TX 77807-1107
United States
Phone: 979 446 0027

---

Officers

Exchange: NYSE MKT

Country: US

Currency: US Dollar ($)